AFP and neoplasm: Therefore, in tumor patients with high CCI at time of discharge, we should justify the use of a tailored immunosuppression (i.e., everolimus, rapid steroid withdrawal), a more cautious use of steroid boluses in the management of acute rejections, or a personalized scheme of outpatient follow-up (i.e., more frequent measurements of alpha-fetoprotein or a more stringent imaging protocol).